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Abstract 24 
 25 
Pan viral DNA microarrays, which can detect known, novel and multiple viral 26 
infections, are major laboratory assets contributing to the control of infectious diseases. 27 
The large quantity of ribosomal RNA (rRNA) found in tissue samples is thought to be a 28 
major factor contributing to the comparatively lower sensitivity of detecting RNA viruses, 29 
as a sequence-independent PCR is used to amplify unknown samples for microarray 30 
analysis. This study aimed to determine whether depletion or exclusion of rRNA can 31 
improve microarray detection and simplify its analysis. The use of two different rRNA 32 
depletion and exclusion protocols, RiboMinus™ technology and non-rRNA binding 33 
hexanucleotides, was compared with the standard global nucleic acid amplification 34 
protocol. This study concludes that the two procedures, described to deplete or exclude 35 
rRNA, have little effect on the microarrays detection and analysis and might only in 36 
combination with further techniques result in a significant enhancement of sensitivity. 37 
Currently, existing protocols of random amplification and background adjustment are 38 
pertinent for the purpose of sample processing for microarray analysis. 39 
 40 
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1.0 Introduction 43 
 44 
The control of viral diseases is reliant on identifying the causative agent in order 45 
to help devise and implement appropriate control measures. Virus identification is less 46 
challenging when probing known viral diseases, in particular, those with characteristic 47 
clinical signs. However, some viral diseases are not pathognomonic and therefore 48 
challenging to diagnose as is the case when unknown or new viruses are involved. Most 49 
detection assays are dependent on the availability of antibodies, antigens or sequence 50 
information, requirements, which are often lacking when investigating novel or divergent 51 
pathogens.  52 
Infectious diseases are continuously emerging in new species and geographical 53 
locations due to factors such as pathogen mutations, genetic reassortment, animal and 54 
human movement and climate change. In this regard, RNA viruses are of particular 55 
concern, as they mutate at a higher rate than DNA viruses and lack proofreading enzymes 56 
to prevent errors during RNA replication (Holland et al., 1982). The constant threat of 57 
new infectious diseases reiterates the need for rapid and multiplex detection assays such 58 
as microarrays, which can probe thousands of viruses simultaneously. In addition, these 59 
assays have the potential to detect viruses closely related to known viral pathogens and 60 
viral co-infections. Microarrays, however, do not come without challenges.  61 
Ribosomal RNA (rRNA) is estimated to make up 80 % of total cellular RNA, being 62 
comprised mostly of 28S and 18S rRNA species in mammals (de Vries et al., 2011). The 63 
necessary use of sequence independent amplification to process tissues from unknown 64 
viral diseases results in co-amplification of host along with viral nucleic acids. This non-65 
specific amplification is also thought to complicate the interpretation of readout values 66 
due to cross hybridisation. The rRNA may also compete with viral RNA amplification and 67 
instigate lower detection sensitivity. Ribosomal RNA depletion methods, such as 68 
RiboMinusTM technology (Life Technologies), were stated to improve microarray analysis 69 
(Gilbert et al., 2010, Kang et al., 2011). In the RiboMinusTM protocol, rRNA molecules are 70 
depleted from total RNA using biotin labelled oligonucleotide probes, which hybridize to 71 
18S, 28S, 5.8S and 5S rRNA before being removed with streptavidin-coated magnetic 72 
beads. The procedure has been found to reduce large rRNA by 80 % (Gilbert et al., 2010).  73 
 74 
 75 
Endoh and colleagues (2005) have used a mix of 96 non rRNA binding hexamers, screened 76 
from 4096 hexamers, to exclude rRNA molecules from amplification. The procedure was 77 
claimed to decrease the amount of non specific amplification and enhance the sensitivity 78 
of a virus discovery assay. The 96 hexamers were also shown to reduce rRNA 79 
amplification by >90% and to improve sensitivity of high throughput sequencing (de Vries 80 
et al., 2011). The hexamers also increased microarray specificity and simplified its 81 
analytical process (Kang et al., 2011). These studies, however, only looked at viruses 82 
isolated in cell culture and nasal swabs. 83 
The analytical process of microarrays is also complex and the interpretation of the 84 
output files is likely to be challenging (Kang et al., 2011) although bioinformatic tools have 85 
already been developed to improve and simplify data analysis, such as the DetectiV 86 
software (Watson et al., 2007). Some studies have looked at optimising sample 87 
processing, such as, reducing genomic DNA and optimising hybridisation conditions 88 
(Kang et al., 2011, Han et al., 2006). Although these steps have improved microarray 89 
detection rate significantly, cross hybridisation and a comparatively low sensitivity still 90 
remain problematic when testing tissue samples. This study therefore compared the 91 
application of rRNA depletion or exclusion methods using tissue samples to investigate if 92 
either method can improve microarray detection of RNA viruses and simplify microarray 93 
analysis in comparison with the standard random priming protocol. 94 
95 
2.0 Materials and methods 96 
 97 
2.1 Samples and nucleic acid extraction 98 
A selection of virus positive tissue samples were used in this study (Table 1). 99 
Tissue samples were homogenised and RNA was extracted using QIAamp® Viral RNA 100 
Mini kit (Qiagen) for tonsil samples or TRIzol (Life Technologies) for brain samples 101 
following the manufacturers’ protocols. Nucleic acid was quantified using Nanodrop 2000 102 
spectrometer (Agilent Technologies) and diluted to a concentration of 4 g in 32 l of 103 
nuclease free water, from which three aliquots of 8 l were subjected to DNase digest 104 
using amplification grade DNase I (Life Technologies). Briefly, 1 l of 10x DNase buffer 105 
and 1 l of DNase I enzyme (1 units/l) were added to each 8 l nucleic acid extract and 106 
incubated at 37 °C for 30 minutes. 1 l of 25 mM EDTA was then added to the mix and 107 
incubated at 65 °C for 10 minutes to inactivate the DNase I enzyme.  108 
 109 
2.2 Depletion of rRNA using RiboMinusTM Technology 110 
 111 
Ribosomal RNA was removed from one of the DNase digested aliquots of nucleic 112 
acid using the RibominusTM Eukaryote Kit for RNA-Seq (Life Technologies) according to 113 
the manufacturer’s protocol. Briefly, for each viral extract, nucleic acid was added to 10 114 
l of RiboMinusTM probe (15 pmol/l) and 100 µl of hybridization buffer and incubated 115 
at 70-75 °C for 5 minutes. The sample was transferred to prepared RiboMinusTM Magnetic 116 
beads and incubated at 37 °C for 15 minutes. The beads were separated using a magnet 117 
leaving RiboMinusTM RNA (target RNA) in the supernatant, which was transferred into 118 
fresh RiboMinusTM beads. The sample was incubated at 15 °C for 15 minutes and the beads 119 
were separated. The nucleic acid was finally precipitated with ethanol and re-suspended 120 
in 11 µl of water before being converted into cDNA using the random priming protocol 121 
(section 2.3.1). 122 
 123 
2.3 cDNA synthesis 124 
 125 
2.3.1 Using random primer A (random priming) 126 
The tailed primer A, 5’ GTT TCC CAG TCA CGA TAN NNN NNN NN 3’, referred to 127 
hereafter as primer A, was used to generate random cDNA from the rRNA depleted nucleic 128 
acid, from the RibominusTM protocol, and the second aliquot of nucleic acid as described 129 
by Wang et al., (2002). Briefly, 1 l of 12.5 mM dNTP (Promega) and 1 l of 40 M primer 130 
A were added to each of the two aliquots. The mixtures were then heated at 95 oC for 5 131 
minutes and chilled on ice immediately. 4 l 5 x RT buffer (Life Technologies), 1 l 0.1M 132 
DTT, 1 l RNasin Ribonuclease inhibitor (20-40 u/l, Promega) and 1 l Superscript III 133 
(200 u/l) (Life Technologies) were then added and the mix was incubated at 25 °C for 5 134 
minutes, 42 °C for 60 minutes and 70 °C for 15 minutes to stop the reaction.  135 
 136 
2.3.2 Using the 50 hexamers 137 
The third aliquot of nucleic acid was converted into cDNA using the 50 hexamers 138 
(section 3.1) and following the random priming protocol, but replacing the primer A with 139 
the 50 hexamers at a concentration of 80 M.  140 
 141 
2.4 Second strand DNA synthesis and nucleic acid amplification 142 
This was carried out as described by Wang et al., 2002 with minor modification 143 
for the cDNA generated using the 50 hexamers. Briefly, cDNA was denatured at 94 C for 144 
2 minutes and cooled to 10 C before adding Sequenase enzyme mix [2 l 5x Sequenase 145 
buffer (Affymetrix), 0.3 l Sequenase DNA polymerase and 7.7 l water]. This mix for the 146 
cDNA generated with the 50 hexamers had an additional 1 l of 40 µM primer A. The 147 
reactions were heated from 10 C to 37 C over an 8 minute period using a Veriti 148 
thermocycler (Life Technologies) and held at 37 C for another 8 minutes before being 149 
terminated at 94 C for 2 minutes. Amplification of the double-stranded DNA (dsDNA) 150 
was performed using a mix containing 5 l 10x KlenTaq PCR buffer (Sigma Aldrich), 1 l 151 
12.5 mM dNTP mix, 1 l 100 µM primer amino-B (amino-C6 5’ GTT TCC CAG TCA CGA TA 152 
3’), 0.5 l KlenTaq® LA DNA polymerase (5 units/l), 5 l of template and water to a total 153 
volume of 50 l. The thermal profile used was 94 C for 4 minutes, 68 C for 5 min then 154 
35 cycles of 94 C for 30 seconds, 50 C for 1 min, 68 C for 1 min and a final extension of 155 
68 C for 2 minutes. The amplified PCR products were run on a 2% agarose gel with SYBR® 156 
safe DNA gel stain (Life Technologies) and visualised on a trans UV illuminator (Bio Rad), 157 
which should show a smear between 200 and 1000 bp (Chen et al., 2011). 158 
 159 
2.5 Labelling DNA with fluorescent dye  160 
Indirect labelling of the amplified DNA templates (5 l) was performed using 15-161 
20 cycles of PCR which incorporates amino allyl dUTP (Life Technologies) into the 162 
reaction (Gurrala et al., 2009). The labelled products were purified using the MinElute 163 
PCR purification Kit (Qiagen) following the manufacturer’s protocol, substituting the 164 
wash buffer with 75 % ethanol and eluting the sample in 13 l of water. The fluorescent 165 
dye was coupled to the amino allyl labelled PCR product by adding 6 l of Sodium 166 
Bicarbonate (25 mg in 1 ml of water) and 4 l of Alexa Fluor® 647 Reactive Dye (Life 167 
Technologies), reconstituted in 18 l of DMSO, to the eluted DNA, vortexing and 168 
incubating at room temperature in the dark for up to two hours. The unincorporated dye 169 
was removed using the illustraTM AutoSeqTM G-50 Dye terminator removal Kit (GE 170 
Healthcare), according to the manufacturer’s protocol. The labelled DNA was quantified 171 
on the Nanodrop 2000 spectrophotometer (Agilent Technologies). 172 
 173 
2.6 Microarray hybridization, slide washing, scanning and data analysis 174 
The pan-viral microarray chip used in this study contained 47,000 probes (60 175 
mers) to around 2,500 virus species. The chip was printed by Agilent Technologies in an 176 
8 x 60K format so that 8 samples could be processed simultaneously.  177 
The hybridization mix was composed of 2.5 l Cot-1 DNA (1.0 mg/ml, Kreatech 178 
Diagnostics), 5 l Agilent 10X blocking agent, 25 l Agilent 2X hi-RPM buffer and 17.5 l 179 
of the labelled product. The mix was heated on a thermocycler at 95 °C for 3 minutes and 180 
37 °C for 30 minutes before being applied onto the gasket slide. A microarray slide was 181 
then lowered onto the gasket slide and secured inside an Agilent hybridization chamber. 182 
The chamber was placed into a pre-heated rotating hybridization oven (Agilent 183 
Technologies) at 65 °C and set to rotate at 10 rpm overnight. The slide, whilst attached to 184 
the gasket slide, was submerged into room temperature Agilent Oligo aCGH/Chip-on-chip 185 
wash buffer 1 (Agilent Technologies) to remove the gasket slide. The microarray slide was 186 
then transferred into a fresh jar of the buffer and stirred using a magnetic stirrer for 5 187 
minutes. The slide was subsequently transferred into pre-warmed 37 °C buffer 2 and 188 
stirred for another 1 minute before being scanned. The slide was scanned on a microarray 189 
Agilent C scanner with 2 micron resolution as instructed by the manufacturer. The output 190 
file from the Feature Extraction software of the scanner was analysed using DetectiV 191 
software in R (http://www.R-project.org) (Watson et al., 2007), using data from an 192 
unrelated experiment to correct for the background noise. Results were compared based 193 
on whether the correct virus was identified within the top virus hits when using the p-194 
value and/or average of normalised signal intensities. 195 
 196 
2.7 Quantitative PCR (qPCR) 197 
The virus specific real time PCR mix for all viruses except rabies virus (RV) was 198 
composed of 1 X QuantiTect Virus + ROX Vial Kit (Qiagen), forward and reverse primers 199 
at a final concentration of 0.4 mM and virus specific TaqMan probe at a final concentration 200 
of 0.2 mM, 1X ROX, 3 l of template DNA and water to total a volume of 20 l ( McGoldrick 201 
et al., 1998; Lanciotti et al., 2000; Marriott et al., 2006; Bilk et al., 2012) The thermal profile 202 
used was 95 °C for 5 minutes and 45 cycles of 95 °C for 15 seconds, 60 °C for 45 seconds. 203 
The 18S rRNA real time PCR was performed using 0.6 l 18S rRNA primers/probe mix 204 
(Life Technologies), the QuantiTect Virus + ROX Vial Kit as described above and 2 l 205 
template DNA. For RV, 10 µl Brilliant® II SYBR® Green QPCR with low ROX master mix 206 
(Agilent Technologies) was used with JW12 & N165-146 primers, each totalling a final 207 
concentration of 1 mM, 3 l template DNA and water to a final volume of 20 l (Wakeley 208 
et al., 2005). The thermal profile used was 94 °C for 2 minutes, 45 cycles of 95 °C for 1 209 
minute, 55 °C for 30 seconds and 72 °C for 20 seconds. Each sample was tested in 210 
duplicate and a no-template control (NTC) was also included in each run to check for cross 211 
contamination and background noise. 212 
 213 
214 
3.0 Results 215 
 216 
3.1 Selection and assessment of the non-rRNA binding hexanucleotides 217 
The 50 hexamers used in this study (Supplement 1) were selected from a list of 218 
96 hexamers described by Endoh et al., 2005 using a mathematical script to blast the 96 219 
hexamers against additional sequences, equine 18S rRNA, porcine 18S rRNA, bovine 18S 220 
& 28S rRNA, and human 18S & 28S rRNA sequences (accession numbers AJ311673, 221 
AY265350.1, DQ222453 and U13369 respectively). This was to exclude further hexamers 222 
which share identical DNA sequences with these rRNAs. The ensuing 50 hexamers were 223 
then mapped to genome sequences of several viruses of human and animal importance 224 
(Table 2). This was to assess the number of binding sites of the 50 hexamers on the viral 225 
genomes and also to measure the nucleotide distance between the binding sites. Among 226 
the viruses used, Louping Ill virus (LIV) genome had the lowest binding sites and also the 227 
largest distance between the binding sites, prompting us to include this virus in the study 228 
to evaluate the efficiency of the 50 hexamers in generating cDNA.  229 
Furthermore, in order to assess whether the 50 hexamers performance could be 230 
influenced by low viral load, serial 10-fold dilutions of a Classical Swine Fever virus 231 
(CSFV) positive nucleic acid were made in nucleic acid derived from a virus negative 232 
tissue. The nucleic acid dilutions were then subjected to cDNA synthesis using the 50 233 
hexamers or random priming followed by CSFV qPCR to quantify the virus-specific 234 
amplicons. The Ct values, obtained by the qPCR for each of the CSFV nucleic acid dilutions 235 
using either of the two protocols, were comparable with only minor differences. The 236 
average CSFV Ct values for random priming were 25.3, 24.2, 27.9, 31.2 compared to 26.6, 237 
24.1, 27.1 and 30.8 for the 50 hexamers using neat, 10-1, 10-2 and 10-3 CSFV dilutions 238 
respectively.  239 
 240 
3.2 Visual comparison of gel electrophoresis images of amplicons 241 
The three methods, the 50 hexamers, RiboMinusTM, and random priming, 242 
produced PCR amplicons of the expected size range, with smears of 200 to 1000 bp, on 243 
agarose gel electrophoresis (data not shown) using CSFV, LIV, West Nile virus (WNV) and 244 
RV positive nucleic acids as targets. The 50 hexamers were found to be just as efficient as 245 
the random priming in producing cDNA, even for viruses with few binding sites for the 246 
hexamers, such as LIV. In addition, the use of hexamers resulted in the most evenly spread 247 
DNA smears, indicating an arbitrary amplification of total nucleic acid. 248 
  249 
3.3 Relative qPCR of cDNA and PCR amplicons for virus specific product and rRNA 250 
Virus specific qPCRs were carried out to quantify the amount of virus amplicons 251 
obtained for each virus using the 50 hexamer, RiboMinusTM and random priming 252 
protocols (Table 3). Considering the Ct values, there appears to be no pattern to suggest 253 
that any of the three protocols are contributing to a higher sensitivity in amplifying viral 254 
nucleic acid extracted from tissues samples. The removal or exclusion of rRNA from virus 255 
positive tissues was also quantified by an 18S rRNA qPCR using cDNA, generated with the 256 
50 hexamers, RiboMinusTM and random priming protocols, as template (Table 4). The 257 
cDNAs generated with the 50 hexamers showed marginal effect whilst the RiboMinusTM 258 
protocol demonstrated a clear decrease in rRNA, compared to those cDNAs generated 259 
with random priming protocol. 260 
 261 
3.4 Analysis of virus amplicons generated from the three protocols by microarray 262 
The effect of removing rRNA on microarray specificity, sensitivity and ease of data 263 
interpretation was assessed by analysing microarray outputs from the three protocols 264 
and seven known positive virus samples. Averages and p-values of probes’ fluorescent 265 
intensity from each virus, calculated by the DetectiV software, were considered in the 266 
interpretation of microarray outputs. The 50 hexamers, RiboMinusTM and random 267 
priming had 86 %, 71 % and 86 % detection rates respectively if p values of probes signal 268 
intensity were considered for virus identification. The only difference was in the detection 269 
of low CSFV where the RiboMinus™ protocol used for sample processing. The detection 270 
rate was; however, 100 % for the three protocols when the averages of signal intensity of 271 
virus probes were interrogated to identify the target virus. 272 
To investigate whether depletion or exclusion of rRNA could reduce cross 273 
hybridization of the target virus nucleic acid with unrelated probes on the microarray, the 274 
proportion of variance between average of probes fluorescent intensity for the top virus 275 
hit and those of 19 unrelated viruses was visualised using Scree plots (Fig. 1). Visually, 276 
there was no difference in the reduction of cross hybridisation frequency among the three 277 
methods; however this is subject to an individual’s interpretation of results. The three 278 
sample processing protocols showed a large difference in the average frequency from the 279 
target virus to the unrelated virus hits enabling a clear identification of target virus. 280 
281 
4.0 Discussion 282 
 283 
Microarray has proven to be a successful tool in detecting novel viruses and viral 284 
co-infections establishing itself as a front-line diagnostic tool for investigation of 285 
emerging infectious diseases. Enhancing assay’s performance and thereby simplifying 286 
interpretation of its output is therefore critical for its use in routine diagnostic testing. 287 
Improvements have already been made in the analytical process by using statistical 288 
software, such as DetectiV (Watson et al., 2007), to enable an easier analysis and 289 
interrogation of microarray outputs. Many groups have also attempted to improve sample 290 
preparation (Han et al., 2006, Nicholson et al., 2011, Kang et al., 2011) whilst others 291 
worked on depleting rRNA from extracted nucleic acid for the same purpose (Kang et al., 292 
2011, Gilbert et al., 2010, Endoh et al., 2005). This study looked at implementing two 293 
different rRNA depletion or exclusion methods to assess whether an improvement to 294 
microarray detection of RNA viruses from tissue samples could be made. RiboMinus™ 295 
technology and non-rRNA binding hexamers were the two methods used in this study and 296 
compared with the in-use random priming method. The 50 hexamers were selected from 297 
the originally described 96 hexamers (Endoh et al., 2005) to further reduce rRNA binding 298 
hexamers in order to increase their selectivity towards viral RNAs.  299 
The 50 hexamers did not hamper amplification of virus nucleic acid from tissue 300 
samples, even from those samples with low viral load. However, only a small decrease in 301 
18S rRNA load could be achieved by the hexamers with no repercussion on microarray 302 
detection. On the contrary, de Vries at al (2011) found non rRNA binding hexamers 303 
reducing 28S rRNA amplification by up to 100 fold depending on the region of the rRNA 304 
genome used for quantification. The work, however, was carried out using only 305 
nasopharyngeal swabs which have trivial amounts of cell contamination in comparison to 306 
tissue samples. Furthermore, as a commercial primers-probe mix was used in the study, 307 
it was not possible to verify which region of 28S or 18S rRNA genome was targeted by the 308 
PCR for comparison. 309 
RiboMinusTM technology was successful in removing rRNA to a large extent, as 310 
also indicated by other researchers (Gilbert et al., 2010). However, no difference in 311 
microarray detection was observed compared to the random priming protocol, especially 312 
when applied to deplete rRNA from samples with a low viral load. This may be due to the 313 
length of nucleic acid handling time and several steps of separations and washes in the 314 
RiboMinusTM protocol, causing degradation and poor recovery of viral nucleic acid. 315 
Therefore, the protocol may have removed rRNA effectively, but in the mean time 316 
adversely affected viral nucleic acid integrity. In addition, RiboMinus™ Technology is 317 
comparatively expensive and time consuming, which restricts its application where a high 318 
throughput testing is sought. For these reasons, it would be unrealistic to justify 319 
implementing RiboMinus™ Technology, unless it was highly effective at improving a test, 320 
which we cannot confirm for microarray.  321 
On the whole, the microarray results for all three methods showed no difference 322 
in the overall detection rates and the amount of cross hybridisation seen. Kang at al, 323 
(2011) found that non-ribosomal hexanucleotides had improved the microarrays 324 
specificity. However, all the samples used in the evaluation were virus isolates, which 325 
often contain a small amount of cellular contamination and therefore cannot represent 326 
tissue samples used for microarray analysis in its intended clinical application. In 327 
addition, no parallel comparison was made, using random priming, to verify their 328 
findings. The script used to run the DetectiV software may also have been a major 329 
contributing factor for equal performance of the three protocols seen in this study, 330 
especially when analysing cross hybridisation. The software employs a script with 331 
instructions to subtract florescence data of an unrelated sample from those of an in-test 332 
sample. This background adjustment has already minimised the effect of cross 333 
hybridisation signals and may have contributed to the comparable outcome for the three 334 
protocols. The importance of using signal averages in addition to p-values in microarray 335 
analysis was also identified, as the detection rate was found to be lower when using the 336 
p-value only. The original work describing the DetectiV software (Watson et al, 2007) has 337 
relied only on the p values to analyse microarray outputs. Finally, tissue samples from 338 
experimental conditions, which harbour a higher load of rRNA, compared to cell culture 339 
isolates, may have rendered a lower efficiency for the rRNA exclusion of the 50 hexamers. 340 
The short length of hexamers and consequently non specific binding may also contribute 341 
to the findings of this study, therefore longer oligonucleotides e.g. nonamers may be more 342 
applicable. 343 
In conclusion, this study identified that the two rRNA depletion or exclusion 344 
protocols have no significant effect on microarray detection or reduction in cross 345 
hybridisation. Accordingly, the current random amplification and background adjustment 346 
protocols are pertinent for the purpose of investigating novel and emerging diseases via 347 
microarray analysis whilst the findings also emphasize the importance of selecting the 348 
most appropriate samples for analysis. Protocols suggesting improvement for nucleic acid 349 
preparation should also include tissue samples on validation if intended for diagnostic 350 
purposes. 351 
  352 
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Table 1 
List of viruses used in this study 
 
CSFV, Classical Swine Fever Virus; SBV, Schmallenberg Virus; RV, Classical Rabies Virus; WNV, West Nile Virus; LIV, Louping ill Virus.  
 
Virus Genus Strain 
Original 
host 
Country of 
origin 
Tissue 
type 
CSFV Pestivirus CBR/93 Porcine Thailand 
Porcine 
tonsil 
SBV 
Orthobunyavir
us 
NA Ovine England Ovine brain 
RV Lyssavirus CVS 11 Laboratory adapted 
Murine 
brain 
RV Lyssavirus 404 Mongoose South Africa 
Murine 
brain 
WNV Flavivirus DAKAR unknown Africa 
Murine 
brain 
WNV Flavivirus NY99 unknown USA 
Murine 
brain 
LIV Flavivirus 
LI 3/1-Arb 
126 
Ovine Scotland 
Murine 
brain 
Supplement 1 
The 50 non-rRNA binding hexanucleotides used in this study 
 
GATATC CGGTTA TATAGC GTACTA GCGATA 
TAGTAT ATTACG CTTGTA TCGATA CAATAT 
TATAGT AGTATC CTATAG GTACCA GTGCTA 
TATATA TGTTAA TAGCTA GTATCA CGACAT 
ATATAT ACTATT TACTAG ACATTA GCTATA 
ACTATA TAACCG AGTAGT ATATTG ATGTTA 
CGTAAT CGATAT GTCTAC CGTCTA TGGTAT 
CTATAC GTATAC TACAAG CTTACA GGATAT 
TATGCG TAGCAC TACCAG CGCTTA TTACTA 
GATACT ATATCG ATAGTA CTCATA ACTCGT 
 
 
Table 2  
The 50 hexamers binding capabilities towards several viral genome sequences 
 
 
 
 
 
Virus name 
Accession 
No. 
No. of binding 
sites in the 
genome 
Max. distance 
between binding 
sites 
(nucleotides)  
Louping ill virus Y07863.1 38 1553 
Rabies virus, strain CVS 11 GQ918139.1 111 949 
West Nile virus, strain NY99 
NC_009942 
 
60 825 
Schmallenberg virus 
HE649912, 
HE649913, 
HE649914 
243 506 
Bovine respiratory coronavirus FJ938066.1 255 430 
Classical swine fever virus, strain Eystrup AF326963.1 149 442 
Border disease virus, strain X818 AF037405.1 165 523 
Bovine viral diarrhoea virus, strain 1-NADL M31182.1 163 522 
Equine arteritis virus X53459.3 105 696 
Porcine reproductive and respiratory 
syndrome virus 
AF046869.1 79 911 
 
Table 3 
Virus specific qPCR of the PCR amplicons generated using the 50 hexamers, RiboMinusTM 
and random priming protocols. 
  
Sample 
Average cycle threshold (Ct) value 
The 50 
hexamers 
RiboMinusTM 
technology 
Random priming 
CSFV (low virus load) 23.33 36.75 23.57 
CSFV (high virus load) 10.59 11.32 16.49 
RV (CVS 11 strain) 26.46 26.12 26.81 
RV (RV404 strain) 26.38 27.33 25.26 
WNV (DAKAR strain) 11.81 12.09 11.52 
WNV (NY99 strain) 13.38 12.62 12.83 
LIV 24.09 23.37 22.8 
NTC No Ct No Ct No Ct 
 
CSFV, Classical swine fever virus; RV, Classical rabies virus; SBV, Schmallenberg virus; WNV, West Nile virus; LIV, Louping ill virus; NTC, no 
template control 
 
Table 4 
Quantitative PCR of 18S rRNA in cDNAs generated using the 50 hexamers, RiboMinusTM 
and random priming protocols. 
 
Sample 
Cycle threshold (Ct) value 
50 
hexamers 
RiboMinusTM 
technology 
Random priming 
CSFV (low virus load) 19.41 24.96 19.99 
CSFV (high virus load) 19.73 22.9 20.54 
RV (CVS 11 strain) 14.77 20.16 13.75 
RV (RV404 strain) 14.53 19.27 12.05 
WNV (DAKAR strain) 13.53 19.7 12.75 
WNV (NY99 strain) 14.12 19.84 12.03 
LIV 13.49 17.66 12.94 
NTC No Ct No Ct No Ct 
 
CSFV, Classical swine fever virus; RV, Classical rabies virus; SBV, Schmallenberg virus; WNV, West Nile virus; LIV, Louping ill virus; NTC, no 
template control 
 
  
Fig 1 
Microarray analysis of PCR amplicons generated using the 50 hexamers, RiboMinusTM and 
random priming protocols.  
 
 
 
 
The top 20 viruses with the highest normalised average of probe fluorescent intensities were considered for analysis. The frequency of the 
average for each of the top 20 viruses was calculated by dividing each average by the sum of all averages.  
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